GlassScriptPhysician profile
Nanni Pidikiti
NPI 1417970518
$13,414.58
in general payments reported to CMS, 2019-2025
34 companies · $5,318 in 2025
The $5,318 reported for 2025 was more than what 92% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $434 · 2020: $402 · 2021: $931 · 2022: $2,037 · 2023: $2,746 · 2024: $1,546 · 2025: $5,318.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,838 · Travel and Lodging: $3,772.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,838.32 |
| Travel and Lodging | $3,772.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $4,964.94 | 2019-2025 | Farapulse, General - Therapies, Rotablator Rotational Atherectomy System Console Kit |
| Penumbra, INC. | $3,725.81 | 2022-2025 | Indigo System, Penumbra System, Smart Coil |
| Astrazeneca Pharmaceuticals LP | $851.78 | 2019-2024 | Wainua |
| Abiomed | $783.96 | 2023-2025 | Impella |
| Medtronic, INC. | $595.91 | 2023-2025 | Onyx Frontier, Symplicity G3 |
| Novo Nordisk INC | $391.54 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $261.51 | 2020-2025 | |
| Surmodics, INC. | $232.85 | 2024 | Pounce Thrombectomy, Pounce Venous Thrombectomy System, Pounce Thrombectomy System |
| Novartis Pharmaceuticals Corporation | $185.81 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $184.46 | 2021-2022 | |
| Amgen INC. | $167.70 | 2021-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $143.56 | 2019-2025 | Lifevest |
| Cvrx, INC. | $131.82 | 2024 | Barostim Neo System |
| United Therapeutics Corporation | $131.75 | 2024-2025 | Tyvaso |
| Avinger INC. | $104.65 | 2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $91.85 | 2019-2020 | |
| Chiesi USA, INC. | $85.21 | 2019-2025 | Kengreal, Cleviprex |
| Merck Sharp & Dohme LLC | $59.63 | 2021-2022 | |
| Veryan Medical Incorporated | $48.50 | 2021 | |
| Cardiva Medical, INC. | $45.80 | 2019-2023 | Cardiva Vascade 6/7f Vcs |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.96 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $26.84 | 2023-2024 | Inpefa |
| Abbott Laboratories | $22.84 | 2025 | Perclose Prostyle |
| Bridgebio Pharma, INC. | $19.97 | 2025 | Attruby |
| Akcea Therapeutics, INC. | $18.94 | 2020 | |
| Cook Medical LLC | $17.80 | 2025 | Icast Covered Stent System, 6mmx22mmx120cm, Zilver Ptx |
| Intact Vascular, INC. | $16.11 | 2019 | |
| Daxor Corporation | $15.39 | 2023 | Bva-100 |
| Biotronik INC. | $15.32 | 2025 | Amvia Edge |
| Terumo Medical Corporation | $14.76 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $13.02 | 2019 | |
| Philips North America LLC | $12.98 | 2022 | |
| Ge Healthcare | $2.61 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$190,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nanni Pidikiti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.